• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Evestra Onkologia awarded R&D grant for endometriosis

Evestra Onkologia awarded R&D grant for endometriosis

January 25, 2017
CenterWatch Staff

Evestra’s wholly-owned Polish subsidiary, Evestra Onkologia has received a major R&D grant. The $4.6 million project, co-financed by the European Union Regional Development Fund, will support development of a drug—EC313—designed to treat endometriosis.

Evestra is a San Antonio-based biopharmaceutical R&D company. Evestra Onkologia is a Poland-based research and development company dedicated to oncology therapeutics.

Dr. Maciej Wierzbicki and an experienced R&D team in Lodz, Poland are spearheading Evestra Onkologia and development of EC313. They will collaborate with Polish and international experts and opinion leaders.

“We are grateful to the Polish National Centre For Research and Development for awarding Evestra Onkologia this prestigious grant, and recognizing the innovative approach taken by Evestra to generate EC313 as a promising drug to treat endometriosis,” said Evestra President and CEO Ze’ev Shaked. “This grant validates the strategic approach we have taken to drug development since we launched Evestra in 2008.”

“EC313 was designed through intensive efforts in structure-activity relationships (SAR), which has led to a new generation of selective progesterone receptor modulator (SPRM) compounds and so-called mesoprogestins,” said Evestra’s Chief Scientific Officer Dr. Klaus Nickisch. “These mesoprogestins have an optimal tailor-made ratio of agonistic to antagonistic activity, which is required for a particular gynecological treatment.”

EC313 has demonstrated significant superiority over other SPRMs, Shaked said. Evestra completed the discovery work on EC313 and holds an international patent covering EC313 and other new chemical entities (NCE).

Endometriosis is a common gynecological condition affecting an estimated 10% of women of childbearing age. According to the Centers for Disease Control and Prevention, endometriosis is when the kind of tissue that normally lines the uterus grows somewhere else such as on the ovaries, behind the uterus, on the bowels, or on the bladder. This "misplaced" tissue can cause pain, infertility and other problems.

Upcoming Events

  • 25Apr

    Effective Root Cause Analysis and CAPA Investigations for Drugs, Devices and Clinical Trials

  • 26Apr

    FDA’s New Laws and Regulations: What Drug and Biologics Manufacturers Need to Know

  • 27Apr

    Califf’s FDA, 2023 and Beyond: Key Developments, Insights and Analysis

  • 17May

    2023 WCG Avoca Quality Consortium Summit

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • tablet

    Digital Intake Platforms Effective as Source of Trial Information, Survey Shows

  • Diversity-360x240.png

    Site Spotlight: EmVenio Research Takes to the Road to Promote Trial Diversity

  • Five Ws

    Consider the Five ‘W’s to Understand Potential Participants

  • QandA-360x240.png

    Perspectives from Smaller-Sized CROs: Q&A with Cheryle Evans

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing